MAP2K7 and melanoma: Another drug trio, targeting MEK (PD-901), CDK4/6 (palbociclib) and mTORC1/2 (AZD2014), has reduced colony formation and S6 phosphorylation in MEKi/CDK4/6i-resistant melanoma, and significantly induced apoptosis in NRAS-mutant melanoma, but it is of note that the treatment success might be hindered by increased toxicities [174].